 |
14 Diseases |  |
33 Trials |
|
33 Trials |  |
2648 News |  |
| «12...1314151617181920212223...3233» |
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-world patient-reported outcomes in RRMS patients transitioning to alemtuzumab: results from the PRO-ACT study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1024;
Significant improvements in employment and household productivity were seen after switching, which may reflect a reduction in the burden that MS imposes on patients with employment and household responsibilities. Alemtuzumab safety was consistent with the pivotal studies.
- glatiramer acetate / Generic mfg.
[VIRTUAL] Effect of disease-modifying treatments on cognitive impairment in MS (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_946;
However, the comparison of results is limited by inhomogeneity between groups (more severe patients in the NTZ group) and the performance of tests at different times (older tests for the NTZ and IFN/AG groups). In conclusion, in our study NTZ was a more effective treatment alternative than FTY, TRF and IFN/AG in reducing cognitive impairment.
- teriflunomide / Generic mfg.
[VIRTUAL] Teriflunomide and cognition: a longitudinal study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_945;
Results suggest that TRF treatment in RRMS has a positive effect in cognitive functioning, and specifically on long term verbal memory, and, to a lesser extent, in inhibition. Neuroimaging correlates are currently being processed and will be presented during the meeting.
- Ponvory (ponesimod) / J&J
[VIRTUAL] Relationships between brain volume and disability, cognition, motor function, and MS-fatigue in RMS: MS-fatigue and ambulation move at their own pace (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_937;
The OPTIMUM study compared ponesimod (20mg) to teriflunomide (14mg) over 108 weeks. There are statistically significant relationships between BV and clinical outcome measures of disability, cognition, motor function, and MS-fatigue; however, ambulation and MS-fatigue were not associated with the PBVC.
- Ponvory (ponesimod) / J&J
[VIRTUAL] Effect of ponesimod compared with teriflunomide on treatment with concomitant corticosteroids for relapse in patients with relapsing forms of multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_927;
P3
Reference: Kappos L et al. JAMA Neurol .
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 (inactivated and mRNA) vaccine and humoral response in people with multiple sclerosis: Chilean cohort (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_907;
In our cohort, most of the treatments are likely to produce humoral response to the COVID-19 vaccine, especially alemtuzumab, cladribine and natalizumab, regardless the infusion/administration time. Further study needs to be done that includes more patients with antiCD20 and fingolimod but also it is important that the studies take into consideration the type of vaccine (T cell dependent response), B cell reconstitution and lymphocyte subpopulations for B and T cells.
- Mayzent (siponimod) / Novartis
[VIRTUAL] Safety and tolerability of conversion to siponimod with and without titration in patients with advancing forms of relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_896;
P3
Immediate conversion from other DMTs to siponimod had an acceptable safety and tolerability profile, with no unexpected findings. There was no evidence of a meaningful reduction in heart rate when initiating siponimod in the overall group or in subgroups stratified by prior DMTs, including subjects transitioning from fingolimod to siponimod without dose titration.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] A retrospective review of COVID spike protein antibody development following COVID-19 vaccination in MS patients on disease modifying drugs (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_889;
This study is limited in retrospective design, small un-balanced groups, and lack of longitudinal data. We cannot exclude the possibility of a more robust delayed humoral response.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] IgG immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within MS PATHS (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_876;
Quantifying post-vaccination IgG response across DMTs is crucial to optimize MS management. Data from ongoing sample collection will be presented at the meeting.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_871;
In addition, we found a superior effect of natalizumab on reducing the rate of disability worsening and improving disability. This study demonstrates the capacity of ATE and ATT MSM to evaluate the effectiveness of multiple MS therapies simultaneously.
- vidofludimus (IMU-838) / Immunic
[VIRTUAL] Safety and tolerability of IMU-838, a next-generation DHODH inhibitor in EMPhASIS: a randomized, placebo-controlled phase 2 trial in relapsing multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_869;
P2
In separate phase 2 trials in MS, patients treated with IMU-838 discontinued treatment less frequently and had a lower rate of side-effects typical of DHODH inhibitors than those treated with teriflunomide. The higher selectivity and lower off-target inhibition of protein kinases of IMU-838 may explain the favorable safety and tolerability profile.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Disease-modifying therapy effect on COVID-19 vaccine response in multiple sclerosis patients: data from two New York State Multiple Sclerosis Consortium centers (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_854;
MS patients treated with B-cell depleting medications and S1P modulators have significantly lower seroconversion after COVID-19 vaccination when compared to DMT-naïve patients and other DMT groups. Future studies should determine the risk of severe clinical outcomes in vaccinated patients with no evidence of seroconversion.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder in Colombia (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_838;
No significant differences were observed by sex and treatment type in prognosis and mortality from COVID-19. However, we suggested to carry out robust sample studies to identify the main complicating factors and severity.
- glatiramer acetate / Generic mfg.
[VIRTUAL] Late onset multiple sclerosis Isfahan Iran (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_835;
LOMS patients have high prevalence of comorbidities that differ from adult ms. Furthermore, the family history of MS is statistically significant in our study.
- teriflunomide / Generic mfg.
[VIRTUAL] Real-world assessment of quality of life through patient-reported outcomes in relapsing-remitting multiple sclerosis patients treated with teriflunomide for two years. Outcomes of the AURELIO study in Greece (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_797;
In line with other studies in the teriflunomide clinical development program, AURELIO showed stable QoL, efficacy and safety outcomes, and improved treatment satisfaction in this Greek cohort of RRMS patients. These data highlight the importance of PROs to facilitate personalized treatment strategies in MS.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
[VIRTUAL] Multiple sclerosis patients initiating ofatumumab in the real-world: 6 months data (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_795;
Most patients newly initiated ofatumumab had no treatment in the prior year. Understanding patient profile, prior DMT use in the real-world may help stakeholders guide treatment decisions.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Cladribine in a real world setting. The real patients (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_790;
23 patients switch from teriflunomide, 16 from dimethylfumarate, 14 from fingolimod, 22 from injectables, 1 from alemtuzumab... In the real world cladribine has proved to be effective, safe and very well tolerated.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_788;
In the real world cladribine has proved to be effective, safe and very well tolerated. Our findings suggests that dimethyl fumarate has a lower risk of discontinuation because of treatment failure among both treatment-experienced and treatment-naive patients.
- teriflunomide / Generic mfg.
[VIRTUAL] Patient-reported outcomes to assess quality of life in teriflunomide-treated patients with relapsing-remitting multiple sclerosis: Results of Teri-REAL – a real-world study from Hungary (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_784;
The Teri-REAL findings suggest favourable real-world efficacy and safety outcomes with teriflunomide in a Hungarian RRMS population. The measurement of MSQoL-54 and BICAMS over 2 years in these patients offers a unique perspective to this study.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Relapse during the washout period predicts time to relapse after switching to cladribine (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_781;
Washout durations shorter than two months were associated with fewer washout relapses. Prospective studies are needed to assess if washout period reduction can modify relapse outcomes when switching to cladribine.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Effectiveness of relapsing multiple sclerosis patients switching to teriflunomide following disease progression in a real-world setting (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_779;
Following switch to teriflunomide, patients demonstrated numerical reductions in mean EDSS, and most demonstrated stability or improvement in ARR, MRI lesions, and use of ambulatory aids. Long-term assessment of this cohort may aid in understanding the impact of teriflunomide on clinical outcomes in disease progressing RMS patients.
- glatiramer acetate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Teriflunomide improves quality of life in a Greek cohort of relapsing-remitting multiple sclerosis patients switched from injectables: Subgroup analysis of previously-treated patients in the AURELIO study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_775;
PRO-related data from the AURELIO study suggest that oral teriflunomide was associated with increased treatment satisfaction versus injectable DMTs in this subgroup of patients from Greece. A more convenient route of administration as well as greater perceived efficacy and tolerability likely explain these findings.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] MASTER-2 trial: cladribine tablets in patients with relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis after suboptimal response to prior infusion/oral disease-modifying therapy (interim baseline results) (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_772;
P=N/A
MASTER-2 will report real-world data on the effects of CladT3.5 after a suboptimal response to oral/infusion DMT. Baseline analysis is ongoing and results from a data cut in July 2021 will be shown in the presentation.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Early data suggests diroximel fumarate has high rates of real-world adherence and persistence (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_771;
The finding that higher persistence is seen with newer DMTs vs older DMTs should be explored in future matched comparisons. These data support DRF as a well-tolerated fumarate.
- teriflunomide / Generic mfg.
[VIRTUAL] Fatigue, depression and health-related productivity in multiple sclerosis patients treated with teriflunomide for 2 years in the real-world study TeriCARE (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_770;
After 2 years of teriflunomide, fatigue and depression levels remained low, according to score ranging of MFIS-21 and BDI-II, and work productivity increased. Favourable results in fatigue and depression may also explain the improvement in work productivity (HRPQ-MS v2).
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Therapeutic management of relapsing-remitting multiple sclerosis in France in the recent era (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_764;
Our results suggest that moderately effective first-line DMTs do not always allow an effective control of the disease. Therapeutic management is a key element of current MS care (when switch and to what).
- Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Anti-Spike IgG after BNT162b2 vaccine in a group of multiple sclerosis patients from an exploratory case-control study in Italy (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_757;
In our study, most MS patients produce a serological response to BNT162b2 similar to non-MS controls; however, at-risk DMTs resulted in reduced anti-Spike levels and one ocrelizumab-treated patient did not respond. These observations should be better investigated and replicated in larger studies to support clinical decision in COVID-19 vaccine management.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Effectiveness and safety of early high-efficacy vs. escalation therapy in relapsing-remitting multiple sclerosis in Argentina (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_748;
Our study shows that EHE therapies prevent disease progression, relapses and new MRI lesions and demonstrated no increased risk of specific adverse events when compared to ES therapy. This data should be considered when selecting a specific treatment for MS patients.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Real-world experience with cladribine in the MSBase Registry (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_746;
The most common switches to cladribine are from other high-efficacy DMTs such as Natalizumab or Fingolimod. The annualised relapse rate on treatment is 0.11, consistent with clinical trial data.
- teriflunomide / Generic mfg.
[VIRTUAL] NEDA3PLUS study: 48-week interim results on persistence, clinical and MRI outcomes in RRMS patients treated with teriflunomide in a real-world setting (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_745;
In this population, the high treatment persistence observed at Week 48 might indicate good tolerability and safety. Moreover, most patients were free of clinical and MRI activity indicating good efficacy of teriflunomide in the short-term.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_740;
Objective: To compare the clinical outcomes in patients on DMF and TFL in a real-world setting, where both drugs are licensed as a first-line disease modifying therapy (DMT) for RRMS... Analysis of real-world data showed that in RRMS, DMF treatment was associated with more favorable clinical outcomes compared to TFL.
- teriflunomide / Generic mfg.
[VIRTUAL] The effect of different national treatment strategies on disability outcome in relapsing-remitting multiple sclerosis: a propensity score adjusted comparison between Denmark and Sweden (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_736;
We show for the first time that differences in treatment strategies of RRMS have an impact on disability outcomes at a national level. Escalation of treatment efficacy seemed inferior to using more efficacious DMT as initial treatment.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Cost-effectiveness of ofatumumab in comparison with other disease modifying therapies and best supportive care for the treatment of relapsing-remitting multiple sclerosis in Canada (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_732;
Considering first-line therapies, ofatumumab was dominant (more efficacy, lower costs) over teriflunomide, interferons, dimethyl fumarate, and ocrelizumab, and resulted in incremental cost-utility ratios (ICURs) of $24,177 Canadian dollars per quality-adjusted life-years (QALYs) gained versus glatiramer acetate and $28,034 versus BSC... In Canada, ofatumumab is cost effective against all comparators and dominant compared to all currently approved and reimbursed first-line DMTs for the treatment of patients with RRMS, except glatiramer acetate.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
[VIRTUAL] Effect of ofatumumab on brain volume loss vs historical placebo in relapsing multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_674;
In the phase 3 ASCLEPIOS I/II trials, ofatumumab 20 mg administered subcutaneously every 4 weeks (q4w) was superior to oral teriflunomide 14 mg once daily, with significant reduction in relapse rates, lesion numbers on MRI, neurofilament light levels greater delays in disability worsening in patients with RMS...MRI scans for RMS patients treated with placebo were collected at baseline, month 6, year 1 2 in the FREEDOMS and FREEDOMS II trials, a Phase 3 trials involving fingolimod... Based on our analysis using identical MRI methodology causal inference methods, ofatumumab significantly reduced disease related BVL when compared with placebo.
- teriflunomide / Generic mfg.
[VIRTUAL] Impact of teriflunomide on innate immune cell activation in RRMS patients with limited signs of CNS pathology (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_637;
P=N/A, P4
Innate immune cell activation was not altered during one year of teriflunomide treatment in any region of interest, and the patients remained clinically stable. However, due to the relatively mild nature of the cohort, and the initial low innate immune cell activation, the effect of teriflunomide on progression-promoting microglial activation remains unclear.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Evaluating DMT escalation based on isolated MRI activity (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_570;
Methods : From the Vienna Innsbruck MS database (VIMSD), we included RMS patients (18-65 years) with a) newly initiated moderately effective DMT (interferon-beta, glatiramer acetate, dimethyl fumarate, or teriflunomide) continued for 12 months, b) clinical stability (no relapses or disability progression) on DMT for 12 months, c) MRI at baseline (MRI-0) and after 12 months of DMT (MRI-1), and d) available clinical follow-up for ≥3 years... In our real-world cohort of clinically stable patients, DMT escalation based on isolated MRI activity only changed outcome when MRI activity fulfilled at least MAGNIMS criteria (exceeding 3 new/enlarged T2 lesions).
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
[VIRTUAL] First-hand experience with ofatumumab at ASCLEPIOS study sites in Europe (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_543;
After gaining experience with ofatumumab within clinical trials, European neurologists consider ofatumumab a very efficient and safe treatment option. They rate the self-administered subcutaneous injection once a month as offering high convenience for patients and as facilitating processes at high-occupancy clinics and office-based practices.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
[VIRTUAL] Estimating the long-term clinical and societal outcomes of ofatumumab compared with teriflunomide and evaluating the impact of immediate vs delayed high efficacy therapy in treating patients with relapsing multiple sclerosis in Spain (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_536;
At the end of 10 years, patients receiving ofatumumab are projected to experience comparatively better clinical outcomes than those receiving teriflunomide. Furthermore, a strategy of early use of a HET such as ofatumumab vs its delayed use, has the potential to further improve the clinical outcomes compared to an escalation strategy in RMS patients having characteristics similar to those in ASCLEPIOS trials.
- Ponvory (ponesimod) / J&J
[VIRTUAL] Analysis and evaluation of ponesimod hepatic safety data (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_533;
Introduction: In the OPTIMUM Phase III study, the efficacy and safety of ponesimod 20 mg were compared to that of teriflunomide 14 mg. The pattern of hepatic effects observed with ponesimod treatment in the entire development program is consistent with the S1P class and no cautionary statement on adverse reactions for moderate and severe hepatic impairment categories was included in the label.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] The role of disease modifying therapies in rate and severity of COVID-19 infection in a cohort of MS and NMOSD (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_531;
The risk for No DMT cases were lower than treated ones. Any progression or relapsing in disease course didn't occur in these confirmed infected patients.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Treatment patterns in patients with multiple sclerosis: a single hospital cohort study in Sweden (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_528;
Most patients were treated with a DMT within months of diagnosis, with predominant initial use of interferons, and switching to more potent agents in later lines of therapy. Prescribing patterns are changing and expected to evolve further with earlier use of powerful agents.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] COVID-19 vaccination and humoral immune response in people with multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_520;
Some patients treated with anti-CD20 and fingolimod failed to develop a post-vaccination humoral response. Adverse events were similar to the general population.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Risk of cancer with disease-modifying drugs in multiple sclerosis: a new-user cohort design in the French nationwide claims database (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_471;
Results suggest a trend of increased risk of cancer in patients with MS who initiated IS compared with IIM. Longer follow-up of this patient population is warranted.
- Ponvory (ponesimod) / J&J
[VIRTUAL] Ponesimod demonstrated increased clinical benefit over teriflunomide in early disease subgroup compared with overall population (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_412;
Ponesimod demonstrated increased clinical benefit as compared with teriflunomide in early disease subgroups and compared with the overall population. This subgroup analysis confirms the advantage of using ponesimod as an early high efficacy treatment.
- teriflunomide / Generic mfg.
[VIRTUAL] Oral teriflunomide effect on visual function in multiple sclerosis: multifocal electroretinogram responses after 12 months of treatment (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_384;
After 12 months of teriflunomide oral treatment in RRMS patients, we observed significant improvement in retinal function, revealed by increased wave amplitudes and decreased latencies. Considering lack of a control group, the small sample size and the variability of mfERG explorations, these results require further confirmation.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Disease modifying therapy and pregnancy outcomes in multiple sclerosis: a systematic review and meta-analysis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_355;
Live birth with birth defects in Multiple Sclerosis patients treated with Natalizumab were statistically significant in comparison to Glatiramer Acetate. Whereas Live birth with birth defects in MS patients treated with Fingolimod, Dimethyl Fumarate, Teriflunomide and all Interferons were not significant compare to Glatiramer Acetate.
- teriflunomide / Generic mfg.
[VIRTUAL] Pregnancy-related outcomes in persons with MS exposed to teriflunomide (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_354;
Whereas Live birth with birth defects in MS patients treated with Fingolimod, Dimethyl Fumarate, Teriflunomide and all Interferons were not significant compare to Glatiramer Acetate. Any adverse pregnancy outcomes reported to TFL-exposed males and females are accordant with those of the general population.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 in a neuroimmunology and multiple sclerosis referral unit (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_336;
Los datos de nuestra serie estan en concordancia con otros estudios, mostrando que la esclerosis múltiple per se y los diferentes tratamientos immunomoduladors no son un factor de riesgo para el COVID19. Es importante acelerar la vacunación de los pacientes con esclerosis múltiple para reducir la posibilidad de infección por SARS-CoV-2.
- Ponvory (ponesimod) / J&J
[VIRTUAL] Ponesimod shows improved effect on Brain Volume compared with other DMTs, a model-based meta-analysis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_289;
Based on the MBMA results, ponesimod, the only monospecific S1P1 modulator, has shown improved brain volume data compared with other MS DMTs. Additional studies looking at direct CNS effects of ponesimod could help explain the beneficial effect on BVL.
- teriflunomide / Generic mfg.
[VIRTUAL] Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomised TERIKIDS trial (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_276;
P3
Additional studies looking at direct CNS effects of ponesimod could help explain the beneficial effect on BVL. This preliminary analysis suggests that teriflunomide treatment is associated with a decrease in pNfL levels in children with relapsing MS.